PhD Candidate
University of Toronto
Toronto, Ontario, Canada
Chukwunonso Nwabufo is the founder of OneDrug and a multiple award-winning pharmacologist with over six years' experience in drug development across academia and the pharmaceutical industry. Chuk contributed to the development of Remdesivir and Lenacapavir approved for the treatment of COVID-19 and HIV respectively during his tenure at Gilead Sciences. Chuk has received > 20 awards and recognitions worth more than C$200K in funding. Chuk is the author of 15 peer-reviewed scientific papers and 11 industry-standard peer-reviewed reports in support of drug development programs. Currently, Chuk is a PhD Candidate in pharmaceutical sciences at the Leslie Dan Faculty of Pharmacy, University of Toronto and has received the prestigious Canadian Institutes of Health Research (CIHR) Canada Graduate Scholarship Doctoral (CGS-D) Award, and CIHR CGS-D – Michael Smith Foreign Study Supplements Award to support his research which is investigating pharmacological strategies for improving the clinical efficacy and safety of respiratory medicines, particularly, promising drugs for treating SARS-CoV-2 infection. Chuk serves as an Editorial board member of Drug Metabolism Reviews and Journal of Applied Bioanalysis. He is an abstract screener for PharmSci360 conference and Vice Chair for the Pharmacokinetic, Pharmacodynamic and Drug Metabolism Community of the American Association of Pharmaceutical Scientists, USA.
SARS-CoV-2 Infection Affects Drug Metabolizing Enzymes and Membrane Transporters
Tuesday, October 24, 2023
3:00 PM – 3:15 PM ET